The latest price target for Soleno Therapeutics (NASDAQ:SLNO) was reported by Baird on December 2, 2024. The analyst firm set a price target for $72.00 expecting SLNO to rise to within 12 months (a possible 59.36% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Soleno Therapeutics (NASDAQ:SLNO) was provided by Baird, and Soleno Therapeutics reiterated their outperform rating.

There is no last upgrade for Soleno Therapeutics

There is no last downgrade for Soleno Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Soleno Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Soleno Therapeutics was filed on December 2, 2024 so you should expect the next rating to be made available sometime around December 2, 2025.

While ratings are subjective and will change, the latest Soleno Therapeutics (SLNO) rating was a reiterated with a price target of $72.00 to $72.00. The current price Soleno Therapeutics (SLNO) is trading at is $45.18, which is out of the analyst’s predicted range.